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INTRODUCTION
Drug induced liver injury [DILI] is the most common
cause of fulminant liver failure in the Western hemisphere.
There are databases logging the myriad of herbs,
supplements and medications that can cause DILI.
Gemcitabine, a cytotoxic chemotherapy used most
commonly in lung and pancreaticobiliary malignancy,
has been well described as causing cholestatic liver
injury. There are several case reports remarking on fatal
hepatic failure with gemcitabine. This case describes
steatohepatitis, a pattern of liver injury not previously
described with gemcitabine.

CASE PRESENTATION
This case involves a 51-year-old healthy Caucasian
female who presented to her primary care physician
with jaundice and was found to have a 3 cm pancreatic
head mass. She underwent surgical resection and was
found to have 2 of 17 lymph nodes positive for adenocarcinoma. Her postoperative course was uncomplicated,
and eight weeks later she was started on adjuvant
chemotherapy with single agent gemcitabine for stage
IIB pancreatic adenocarcinoma. Imaging studies before
beginning chemotherapy revealed two arterially
enhancing lesions in the liver consistent with focal
nodular hyperplasia [FNH]. The patient had a reported
history of Gilbert syndrome. She underwent genetic
testing which confirmed homozygosity of UDP- gluconyltrasnsferase1A1*28 (UGT) allele which is associated
with Gilbert’s syndrome. The patient completed six
28-day cycles of standard dose gemcitabine, specifically,
1000 mg/m2 on days 1, 8, and 15 of each cycle. Routine
surveillance CT imaging obtained at the start of cycle 3
revealed new hepatic steatosis. The patient was
continued on gemcitabine and repeat surveillance
imaging obtained at the end of cycle 4 revealed severe
diffuse hepatic steatosis.

DIFFERENTIAL DIAGNOSIS
The patient was referred to a hepatologist. Genetic,
metabolic and autoimmune causes of fatty liver disease
were excluded. Specifically, the patient had laboratory
testing for alpha-1 antitrypsin deficiency, Wilson’s disease,
hemochromatosis, autoimmune hepatitis, primary biliary
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cirrhosis and diabetes. The patient did not drink alcohol
and had a normal body mass index. Additionally, viral
hepatitides were ruled out. A comprehensive review of her
medications did not reveal any known hepatotoxic agents.

OUTCOME AND FOLLOW UP
Subsequently, the patient had a dedicated MRI of the
abdomen which confirmed the CT findings. The
previously reported benign FNH lesions remained
unchanged. The patient underwent a percutaneous liver
biopsy three weeks after completing chemotherapy with
histopathology revealing steatohepatitis with a NASH
CRN score of 5/8 and fibrosis score of 0/8. This is a
standardized scoring system used among pathologists
to define histopathologic changes in the liver. Throughout
cycles 3-6, the patient’s bilirubin peaked at 1.0 mg/dl and
she had a mild elevation of her transaminase and alkaline
phosphatase levels. With the exception of moderate
nausea, the patient tolerated chemotherapy well.
Three months after completing chemotherapy, the
patient had imaging revealing innumerable metastatic
lesions in the liver. She declined further systemic
chemotherapy and had switched institutions to enroll in
an immunotherapy clinical trial. Unfortunately, the
patient succumbed to her disease and died shortly after
her metastases were discovered.

DISCUSSION
In our literature search, there have been few cases
describing gemcitabine associated steatohepatitis. The
primary mechanism by which drugs lead to steatohepatitis is by inducing mitochondrial toxicity and
causing accumulation of lipid byproducts and reactive
oxygen species. There have been several molecular
pathways implicated in pathogenesis of steatohepatitis,
including PPAR and CY2D6 mutation. Common
chemotherapeutic agents well described to cause this
pattern of injury are irinotecan and oxaliplatin. We believe
that gemcitabine is the causative agent of nonalcoholic
fatty liver disease [NAFLD] in this patient. Her NAFLD
progression shows a clear temporal relationship with
gemcitabine introduction and an exhaustive work up
excluded other etiologies. We suspect her steatohepatitis would have resolved with discontinuation of

gemcitabine. Gemcitabine, a pyrimidine antimetabolite,
is not dependent on UGT for glucorindation of its
metabolites. There have been no previously established
links between Gilbert’s syndrome and increased risk of
hepatotoxicity with gemcitabine, as there have with
other drugs, such as irinotecan.

KEY POINTS
We hypothesize that patients with Gilbert syndrome may
be predisposed to the effect of gemcitabine hepatotoxicity. Therefore, we recommend exercising caution in
this patient population and having a low threshold for
discontinuation of gemcitabine if there is elevation in
transaminases or radiographic changes on crosssectional imaging.
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